ClinicalTrials.Veeva

Menu
C

Clinical Research Institute, Inc. | Minneapolis, MN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atogepant
azelastine hydrochloride
Rimegepant
Galcanezumab
Racemic Albuterol
Dupilumab
Levalbuterol
PF-04965842
Erenumab
Indacaterol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 82 total trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Enrolling
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The stu...

Enrolling
Perennial Allergic Rhinitis (PAR)
Drug: Placebo
Drug: LY3650150
Locations recently updated

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in chil...

Active, not recruiting
Respiratory Syncytial Virus
Biological: Placebo
Biological: mRNA-1345

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme dis...

Active, not recruiting
Lyme Disease
Biological: Placebo
Biological: mRNA-1975

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Enrolling
SARS-CoV-2
Biological: mRNA-1273.815
Biological: mRNA-1273.214

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North...

Active, not recruiting
Lyme Disease
Biological: VLA15
Other: Saline
Locations recently updated

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 3
Drug: Erenumab Dose 1

This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treat...

Active, not recruiting
Migraine
Drug: Placebo
Drug: BHV-2100
Locations recently updated

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the air...

Enrolling
Asthma
Drug: dupilumab
Drug: Matching Placebo

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the...

Active, not recruiting
Lyme Borreliosis
Biological: VLA15
Biological: Placebo

This study is to understand if the study vaccine (called VLA15) is safe in healthy children.We are looking for children who:* are healthy* are age 5...

Active, not recruiting
Lyme Disease
Other: Normal Saline
Biological: VLA15

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling
Refractory or Unexplained Chronic Cough
Drug: NOC-110
Other: Placebo

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Pfizer logo
Allergan logo
Moderna logo
Lilly logo
Meda Pharmaceuticals logo
Sumitomo Pharma logo
AbbVie logo
Allergy Therapeutics logo
Amgen logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems